ADXN — Addex Therapeutics Ltd

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: CH
• Exchange: NASDAQ
• Employees: 2
• Website: https://www.addextherapeutics.com

Latest SEC filings for ADXN

• 6-K — 2026-10-08
• 6-K — 2026-10-02
• 6-K — 2026-09-28
• 6-K — 2026-09-25
• 6-K — 2026-08-26
• 6-K — 2026-07-08
• 6-K — 2026-06-30
• 6-K — 2026-06-25
• 6-K — 2026-06-05
• 20-F — 2026-05-15

Latest ADXN news

• 2026-10-10 — Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage (defenseworld.net)
• 2026-10-08 — Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia (globenewswire.com)
• 2026-10-02 — Addex Therapeutics Announces Executive Management Changes (globenewswire.com)
• 2026-09-28 — Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript (seekingalpha.com)
• 2026-09-28 — Addex Therapeutics reports 1H results (seekingalpha_market)
• 2026-09-28 — Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update (globenewswire.com)

Abrir análisis completo

Educational tool only — not investment advice.